Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …

Traditionally, intertumour heterogeneity in breast cancer has been documented in terms of
different histological subtypes, treatment sensitivity profiles, and clinical outcomes among …

Combination cancer therapies aim to improve the probability and magnitude of therapeutic
responses and reduce the likelihood of acquired resistance in an individual patient …

Cisplatin and its platinum analogs, carboplatin and oxaliplatin, are some of the most widely
used cancer chemotherapeutics. Although cisplatin and carboplatin are used primarily in …

Multi-omics approaches are novel frameworks that integrate multiple omics datasets
generated from the same patients to better understand the molecular and clinical features of …

Covering: 2011 to 2014 It is widely accepted that drug discovery often requires a systems-
level polypharmacology approach to tackle problems such as lack of efficacy and emerging …

Despite considerable progress in genome-and proteome-based high-throughput screening
methods and in rational drug design, the increase in approved drugs in the past decade did …

Cancer is a major disease worldwide. Despite progress in cancer therapy, conventional
cytotoxic therapies lead to unsatisfactory long-term survival, mainly related to development …

BRCA1 or BRCA2 inactivation drives breast and ovarian cancer but also creates
vulnerability to poly (ADP-ribose) polymerase (PARP) inhibitors. To search for additional …

Small molecules can affect many cellular processes. The disambiguation of these effects to
identify the causative mechanisms of cell death is extremely challenging. This challenge …